Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Pfizer 2Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Pfizer 2Q

Revenues in the quarter were favorably impacted by $5.4 billion (most of the 58% revenue bump), due to the addition of the legacy Wyeth products.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Pfizer 2Q

2Q Revenues: $17.3 billion (+58%)

2Q Earnings: $2.5 billion (+9%)

YTD Revenues: $34.1 million (+56%)

YTD Earnings: $4.5 billion (-10%)

Comments: Revenues in the quarter were favorably impacted by $5.4 billion (most of the 58% revenue bump), due to the addition of the legacy Wyeth products. Biopharmaceutical revenues, which includes Primary Care, Specialty Care, Established Products, Emerging Markets and Oncology, totaled $15.0 billion in the quarter (+49%). Diversified revenues, inclusive of Animal Health, Consumer Healthcare, Nutrition and Capsugel, totaled $2.2 billion compared to $833 million in 2Q09. Lipitor sales were up 5% to $2.8 billion. Lyrica sales were up 21% to $762 million. Celebrex sales were $604 million (+10%). Viagra sales were $491 million (+16%). Xalatan/Xalacom sales were $449 million (+14%). Norvasc sales were down 19% to $422 million due to the loss of exclusivity in Canada. Enbrel sales (outside U.S. and Canada) were $808 million. Effexor sales were $621 million. Prevnar/Prevenar 13 and Prevnar/Prevenar 7 sales were $569 million and $331 million, respectively.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters